CLVS Clovis Oncology Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 13 November 2019 Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy

   Rubraca® (rucaparib) offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib

2. 07 November 2019 Clovis Oncology Announces Third Quarter 2019 Operating Results

   $37.6M in Rubraca® (rucaparib) net product revenue for Q3 2019, up 65% year over year Net product revenue increased 14% sequentially in Q3 2019 compared to Q2 2019, including sequential U.S. sales increase of 12%

3. 22 October 2019 Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7

   Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its third quarter 2019 financial results on Thursday, November 7, 2019, before the open of the U.S. financial markets. Clovis' senior management will host a conference

4. 11 October 2019 Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

   Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through

5. 29 September 2019 Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

   43.9% confirmed objective response rate (ORR) in 57 RECIST*-evaluable patients with metastatic castration-resistant prostate cancer (mCRPC) and a BRCA1/2 mutation 52.0% confirmed prostate-specific antigen (PSA)

6. 23 September 2019 Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals

   Clovis to acquire rights to discovery program for three additional targets for radionuclide therapy Clovis to pay approximately $12 million in upfront payments to 3B Pharmaceuticals Clovis currently planning to

7. 12 September 2019 Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019

   Updated data from the Phase 2 TRITON2 trial of Rubraca in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Exploratory ARIEL3 analysis for Rubraca maintenance treatment regimen in

8. 28 August 2019 Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference

   Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the 2019 Wells Fargo Healthcare Conference on Thursday, September 5, 2019 at 8:35 AM

9. 22 August 2019 Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024

   Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the initial purchasers of the previously announced offering of the Company's 4.50% Convertible Senior Notes due 2024 (the "notes") in a private placement to